WO2001048190A3 - Therapeutic uses of lna-modified oligonucleotides - Google Patents

Therapeutic uses of lna-modified oligonucleotides Download PDF

Info

Publication number
WO2001048190A3
WO2001048190A3 PCT/IB2000/002043 IB0002043W WO0148190A3 WO 2001048190 A3 WO2001048190 A3 WO 2001048190A3 IB 0002043 W IB0002043 W IB 0002043W WO 0148190 A3 WO0148190 A3 WO 0148190A3
Authority
WO
WIPO (PCT)
Prior art keywords
lna
modified oligonucleotides
therapeutic uses
treatment
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/002043
Other languages
French (fr)
Other versions
WO2001048190A2 (en
WO2001048190A8 (en
Inventor
Henrik Orum
Troels Koch
Jan Skouv
Mogens Havsteen Jakobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exiqon AS
Original Assignee
Exiqon AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exiqon AS filed Critical Exiqon AS
Priority to AU30417/01A priority Critical patent/AU3041701A/en
Priority to EP00990866A priority patent/EP1240322A2/en
Priority to JP2001548703A priority patent/JP2003524637A/en
Priority to IL14969400A priority patent/IL149694A0/en
Priority to CA002395320A priority patent/CA2395320A1/en
Publication of WO2001048190A2 publication Critical patent/WO2001048190A2/en
Publication of WO2001048190A8 publication Critical patent/WO2001048190A8/en
Publication of WO2001048190A3 publication Critical patent/WO2001048190A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to therapeutic applications of LNA-modified oligonucleotides. In particular, the invention provides methods for treatment of undesired cell growth as well as treatment of inflammatory related diseases and disorders. Preferably, administration of an LNA-modified oligonucleotide modulates expression of a targeted gene associated with the undesired cell growth or an inflammatory related disease or disorder.
PCT/IB2000/002043 1999-12-23 2000-12-22 Therapeutic uses of lna-modified oligonucleotides Ceased WO2001048190A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU30417/01A AU3041701A (en) 1999-12-23 2000-12-22 Therapeutic uses of lna-modified oligonucleotides
EP00990866A EP1240322A2 (en) 1999-12-23 2000-12-22 Therapeutic uses of lna-modified oligonucleotides
JP2001548703A JP2003524637A (en) 1999-12-23 2000-12-22 Therapeutic use of LNA modified oligonucleotides
IL14969400A IL149694A0 (en) 1999-12-23 2000-12-22 Therapeutic uses of lna-modified oligonucleotides
CA002395320A CA2395320A1 (en) 1999-12-23 2000-12-22 Therapeutic uses of lna-modified oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17187399P 1999-12-23 1999-12-23
US60/171,873 1999-12-23

Publications (3)

Publication Number Publication Date
WO2001048190A2 WO2001048190A2 (en) 2001-07-05
WO2001048190A8 WO2001048190A8 (en) 2001-10-11
WO2001048190A3 true WO2001048190A3 (en) 2002-05-10

Family

ID=22625473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/002043 Ceased WO2001048190A2 (en) 1999-12-23 2000-12-22 Therapeutic uses of lna-modified oligonucleotides

Country Status (7)

Country Link
US (1) US20020068709A1 (en)
EP (1) EP1240322A2 (en)
JP (1) JP2003524637A (en)
AU (1) AU3041701A (en)
CA (1) CA2395320A1 (en)
IL (1) IL149694A0 (en)
WO (1) WO2001048190A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413701B (en) * 2001-11-06 2006-05-15 Bmt Medizinische Forschung Und STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF CDW92
DE10226702A1 (en) * 2002-06-14 2004-09-09 Grünenthal GmbH Antisense oligonucleotides against PIM1
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
AU2015204315B2 (en) * 2002-11-18 2017-06-22 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
AU2013201763B2 (en) * 2002-11-18 2015-05-07 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
US9045518B2 (en) * 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
JP2006518999A (en) * 2003-02-10 2006-08-24 サンタリス・ファルマ・アクティーゼルスカブ Oligomeric compounds for modification of thioredoxin expression
US20040248840A1 (en) * 2003-02-10 2004-12-09 Santaris Pharma A/S Oligomeric compounds for the modulation of ras expression
PT1592793E (en) * 2003-02-10 2009-09-30 Santaris Pharma As Oligomeric compounds for the modulation of survivin expression
CA2519860C (en) * 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
US7709453B2 (en) * 2003-05-22 2010-05-04 Isis Pharmaceuticals, Inc. Modulation of the RNA interference pathway
WO2005007889A1 (en) * 2003-07-21 2005-01-27 Oncotherapy Science, Inc. Method for diagnosing colorectal cancers
US20050074801A1 (en) * 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
US20060058255A1 (en) * 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
US20090208486A1 (en) * 2004-03-09 2009-08-20 Makoto Taketo Pharmaceutical composition comprising cxcr3 inhibitor
US20060057611A1 (en) 2004-06-30 2006-03-16 Applera Corporation Log-linear amplification
EP2386640B1 (en) 2004-08-26 2015-01-28 EnGeneIC Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
KR20070095882A (en) 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 LAN Oligonucleotides and Cancer
WO2006069584A2 (en) * 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
WO2006081158A2 (en) * 2005-01-25 2006-08-03 The Regents Of The University Of California Predictive and therapeutic markers in overian cancer
AU2006291836B2 (en) * 2005-09-15 2012-02-23 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-Bl00 expression
DK1984382T3 (en) * 2006-01-27 2012-09-03 Santaris Pharma As LNA modified phosphorothiolated oligonucleotides
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
BRPI0713206A2 (en) 2006-06-30 2012-04-17 Applera Corp methods of analyzing bond interactions
WO2008086807A2 (en) * 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
US20090082297A1 (en) * 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
EP2212437A4 (en) 2007-11-07 2011-09-28 Univ British Columbia MICROFLUIDIC APPARATUS AND METHOD FOR THEIR USE
WO2009080779A1 (en) * 2007-12-20 2009-07-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Ceacam1 as a biomarker of psoriasis
CA2712724A1 (en) * 2008-01-29 2009-08-06 Celgene Corporation Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
EP3023494B1 (en) 2008-06-13 2018-11-28 Codexis, Inc. Method of synthesizing polynucleotide variants
US9617599B2 (en) * 2008-09-04 2017-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for detection of cancer based on spatial genome organization
JP2012509878A (en) * 2008-11-21 2012-04-26 アイシス ファーマシューティカルズ， インコーポレーテッド Anti-tumor combination therapy, including docetaxel and antisense oligonucleotide
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
HK1200484A1 (en) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. Polyoligonucleotide compound
WO2013123451A1 (en) * 2012-02-15 2013-08-22 Enzon Pharmaceuticals, Inc. Lna antisense oligonucleotides for the modulation of myc expression
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
SG11201508925WA (en) * 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
ES2770667T3 (en) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Antisense and conjugated oligomers that target PCSK9
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
WO2016041058A1 (en) 2014-09-18 2016-03-24 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
JP2019500899A (en) 2015-11-23 2019-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cellular RNA tracking and manipulation through nuclear delivery of CRISPR / Cas9
WO2017096053A2 (en) * 2015-12-01 2017-06-08 The General Hospital Corporation Methods of reducing expression of x-inactivation escapee genes and autosomal genes
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California DIRECTED EDITING OF CELLULAR RNA THROUGH NUCLEAR DELIVERY OF CRISPR / CAS9
EP3790972A1 (en) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
WO2020117706A1 (en) * 2018-12-03 2020-06-11 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
AR122534A1 (en) 2020-06-03 2022-09-21 Triplet Therapeutics Inc METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003260A1 (en) * 1989-09-01 1991-03-21 Temple University Of The Commonwealth System Of Higher Education Antisense oligonucleotides to c-abl proto-oncogene
WO1998039352A1 (en) * 1997-03-07 1998-09-11 Takeshi Imanishi Novel bicyclonucleoside and oligonucleotide analogues
WO1999014226A2 (en) * 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO2000066604A2 (en) * 1999-05-04 2000-11-09 Exiqon A/S L-ribo-lna analogues

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003260A1 (en) * 1989-09-01 1991-03-21 Temple University Of The Commonwealth System Of Higher Education Antisense oligonucleotides to c-abl proto-oncogene
WO1998039352A1 (en) * 1997-03-07 1998-09-11 Takeshi Imanishi Novel bicyclonucleoside and oligonucleotide analogues
EP1013661A1 (en) * 1997-03-07 2000-06-28 Takeshi Imanishi Novel bicyclonucleoside and oligonucleotide analogues
WO1999014226A2 (en) * 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO2000066604A2 (en) * 1999-05-04 2000-11-09 Exiqon A/S L-ribo-lna analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OBIKA S ET AL: "Synthesis of 2'-O,4'-C-Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3'-endo Sugar Puckering", TETRAHEDRON LETTERS, vol. 38, no. 50, 15 December 1997 (1997-12-15), pages 8735 - 8738, XP004097164, ISSN: 0040-4039 *
WENGEL JESPER ET AL: "LNA (Locked Nucleic Acid).", NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 6-7, June 1999 (1999-06-01), pages 1365 - 1370, XP002180387, ISSN: 0732-8311 *

Also Published As

Publication number Publication date
JP2003524637A (en) 2003-08-19
CA2395320A1 (en) 2001-07-05
WO2001048190A2 (en) 2001-07-05
IL149694A0 (en) 2002-11-10
EP1240322A2 (en) 2002-09-18
US20020068709A1 (en) 2002-06-06
WO2001048190A8 (en) 2001-10-11
AU3041701A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
WO2001048190A8 (en) Therapeutic uses of lna-modified oligonucleotides
EP2253706A3 (en) Antisense modulation of kinesin-like 1 expression
WO2004013310A3 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
AU2003275029A1 (en) Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
AU2001290706A1 (en) Antisense modulation of clusterin expression
CY1108165T1 (en) LOCAL USE OF NF-κB BATTERY FOR THE TREATMENT OF TREATMENT OF ATOPHIC SKIN
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
EP1248794A4 (en) ANTISENSE MODULATION OF SMAD7 PROTEIN EXPRESSION
EP1417216A4 (en) ANTISENSE MODULATION OF BCL2-ASSOCIATED X-PROTEIN EXPRESSION
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
WO2002083184A3 (en) Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
WO2003000656A3 (en) Antisense modulation of transforming growth factor beta receptor ii expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
EP1185696A4 (en) ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN C-DELTA PROTEIN KINASE EXPRESSION
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
EP1248633A4 (en) ANTISENSE MODULATION OF GLYCOGENE SYNTHASE KINASE 3 BETA EXPRESSION
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2004096826A3 (en) Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna)
WO2003044167A3 (en) Antisense modulation of human fxr expression
WO2005025487A3 (en) Oligonucleotides targeting prion diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 149694

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 30417/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2395320

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 548703

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000990866

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000990866

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000990866

Country of ref document: EP